Univariate and multivariate analyses of clinical baseline characteristics identified elevated pre-treatment CEA levels (P = 0.015) and MRI-T3/4 stage (P < 0.001) as risk factors for TRG 1–3, whereas a poorly differentiated adenocarcinoma (P = 0.002) was a protective factor for TRG 1–3 (Supplemental Material eTable 1). The gene discussed is CEACAM5; the disease is adenocarcinoma.